此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study of the Safety and Preliminary Efficacy of NKG001 in Pediatric Patients With Type 1 or Type 2 Spinal Muscular Atrophy

A Single-Center, Open-Label, Single-Arm, Non-Randomized, Single-Dose, Dose-Escalation Investigator-Initiated Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NKG001 Injection in Patients With Type 1 or Type 2 Spinal Muscular Atrophy

This study is a single-center, open-label, single-arm, non-randomized, single-dose, dose-escalation investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, and preliminary efficacy of NKG001 Injection administered via different dosing regimens (intravenous [IV] alone or intravenous combined with intrathecal [IV+IT]) in subjects with Type 1 or Type 2 spinal muscular atrophy (SMA).

A total of 13-21 SMA subjects aged ≤60 months are planned to be enrolled. Based on age at enrollment, subjects will be stratified into two age cohorts for independent evaluation:

Age Cohort 1: subjects aged <24 months at dosing; Age Cohort 2: subjects aged ≥24 months and ≤60 months at dosing.

Eligible subjects must carry 2 or 3 copies of the SMN2 gene.

Note: Subjects with 3 SMN2 copies must be able to sit independently but unable to walk independently.

Four dose cohorts are planned as follows:

S1: 6.0 × 10^13 vg/kg, IV S2: 1.2 × 10^14 vg/kg, IV S3: 6.0 × 10^13 vg/kg, IV + 6 × 10^13 vg/person, IT S4: 6.0 × 10^13 vg/kg, IV + 1.2 × 10^14 vg/person, IT

Subjects in the S1 cohort (2 SMN2 copies and aged <24 months at dosing) and the S2 cohort (2 or 3 SMN2 copies and aged ≤60 months at dosing) will receive a single intravenous administration of NKG001 Injection.

Subjects in the S3 and S4 cohorts will receive a single administration of NKG001 Injection via combined intravenous and intrathecal routes. In each of these two cohorts, the first enrolled subject must have 2 SMN2 copies and be aged <24 months at dosing, while the remaining subjects may have either 2 or 3 SMN2 copies and be aged ≤60 months at dosing.

研究概览

地位

主动,不招人

干预/治疗

研究类型

介入性

注册 (估计的)

21

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Hunan
      • Changsha、Hunan、中国、410008
        • Xiangya Hospital of Central South University

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子

接受健康志愿者

不

描述

Inclusion Criteria

Subjects who meet all of the following criteria are eligible for enrollment in this study:

  1. Subjects aged ≤60 months on the day of dosing, regardless of sex.
  2. Subjects must have a genetically confirmed diagnosis of spinal muscular atrophy (SMA) caused by biallelic SMN1 mutations (deletion or point mutation). SMN2 copy number requirements are as follows:

    • S1 cohort and S2-A cohort: 2 copies of SMN2;
    • S2-B cohort: 3 copies of SMN2;
    • S3 and S4 cohorts: 2 or 3 copies of SMN2.

Notes:

  1. Subjects in the S1 cohort and S2-A cohort may be enrolled regardless of the presence or absence of clinical symptoms.
  2. Subjects with 3 copies of SMN2 must be able to sit independently but unable to walk independently. Independent sitting is defined according to the WHO Multicentre Growth Reference Study (WHO-MGRS) criteria as maintaining an upright seated position with the head erect for at least 10 seconds without support from the arms or hands.
  3. The subject's legally authorized representative (LAR) must understand the purpose, potential risks, and rights associated with the study; agree to the subject's participation in all study procedures, assessments, and visits; and voluntarily sign the informed consent form (ICF).
  4. During the study period, based on changes in the subject's clinical condition, the subject's LAR must be willing to comply with standard-of-care recommendations provided by the investigator, including nasogastric feeding, non-invasive mechanical ventilation, cough assist devices, and other supportive treatments as needed.

Exclusion Criteria

Subjects meeting any of the following criteria will be excluded from participation in the study:

  1. Gestational age at birth <35 weeks (245 days).
  2. During screening, oxygen saturation <96% while awake or asleep without supplemental oxygen or respiratory support.
  3. During screening, subjects with moderate or greater swallowing impairment whose caregivers are unwilling to use alternative feeding methods to oral feeding.
  4. Requirement for invasive ventilation or tracheostomy, or use of non-invasive ventilatory support for an average of ≥12 hours/day during screening.
  5. Positive test results for any of the following: human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, Treponema pallidum antibody, TORCH infection, or Epstein-Barr virus (EBV).
  6. Presence of other severe infections or diseases that may pose unnecessary risk for gene replacement therapy, including but not limited to:

    1. Upper or lower respiratory tract infection requiring medical care or intervention (including systemic therapy, hospitalization, respiratory support, or supplemental oxygen) within 4 weeks prior to dosing, or severe non-pulmonary/non-respiratory infection;
    2. Known epilepsy;
    3. Diabetes mellitus;
    4. Idiopathic hypocalcemia;
    5. Severe cardiovascular or cerebrovascular disease;
    6. Severe hepatic or renal impairment.
  7. Clinically significant abnormal laboratory findings, including:

    • GGT, ALT, total bilirubin, or AST >3.0 × upper limit of normal (ULN) (isolated bilirubin elevation attributable to physiologic neonatal jaundice is not exclusionary);
    • Serum creatinine above the normal range;
    • Hemoglobin <80 g/L or >180 g/L;
    • White blood cell count <4.3 × 10^9/L or >14.2 × 10^9/L;
    • Platelet count <183 × 10^9/L or >614 × 10^9/L;
    • Prothrombin time (PT) prolonged by >1.0-1.5 × ULN.
  8. Anti-AAV9 binding antibody titer >1:50 (measured by ELISA) or anti-AAV9 neutralizing antibody titer >1:200 (cell-based assay). Subjects exceeding these thresholds may undergo one repeat test during screening; subjects meeting eligibility criteria upon retesting may continue screening.
  9. Known hypersensitivity or allergic predisposition to prednisolone acetate, other glucocorticoids, or any excipients of the investigational product.
  10. Previous or planned treatment with other SMA gene replacement therapies (e.g., Zolgensma) during the study period.
  11. Participation in another clinical trial within 1 month prior to screening, or prior participation in a clinical study that, in the investigator's judgment, may affect subject safety or evaluation of the investigational product, even if completed >1 month previously.
  12. Receipt of immunosuppressive therapy within 3 months prior to dosing, or anticipated receipt within 3 months after study initiation, other than protocol-required prophylactic medications. Examples include corticosteroids, cyclosporine, tacrolimus, methotrexate, cyclophosphamide, intravenous immunoglobulin (IVIG), and rituximab.
  13. Current use of, or inability to discontinue during the study, immunomodulatory agents (e.g., thymosin, interferons), medications for myopathy, neuritis, or diabetes (e.g., immunosuppressants, glucocorticoids, insulin), or receipt of plasmapheresis.
  14. Oral treatment with β2-adrenergic agonists within 30 days prior to dosing (except inhaled salbutamol/albuterol).
  15. Anticipated need for major surgery during the treatment period.
  16. Prior to dosing, incomplete or delayed vaccinations according to the national immunization schedule for the subject's age that, in the judgment of the investigator and sponsor, may significantly affect subject safety.
  17. Any other condition that, in the investigator's opinion, makes the subject unsuitable for participation in the study.

    Additional Exclusion Criteria for S3 and S4 Cohorts

    Subjects meeting any of the following criteria will be excluded from enrollment into the S3 and S4 dose cohorts:

  18. Presence of cerebrospinal fluid circulation disorders or related diseases.
  19. Contraindications to lumbar puncture or intrathecal administration, including but not limited to infection at the injection site, signs or symptoms of increased intracranial pressure, implanted cerebrospinal fluid drainage devices, or implanted central nervous system catheters.
  20. Severe scoliosis (Cobb angle ≥50°), severe joint contracture deformities that may interfere with motor function assessments, or planned spinal corrective surgery during the observation period.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:NKG001 administration group
NKG001 Injection

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Participants Who Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs) During the Study.
大体时间:Up to 24 months
Assess the number of AEs and SAEs as characterized by Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Up to 24 months
Incidence of Dose-Limiting Toxicities (DLTs) Within 30 Days After Administration.
大体时间:Up to 30 days
DLTs are defined according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Up to 30 days

次要结果测量

结果测量
措施说明
大体时间
Change From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Score (Participants aged <24 months at dosing)
大体时间:UP to 24 months
Assess 16 types of muscle movements, each given a score from zero (the person can't complete the movement) to 4 (the person can complete the movement on their own, without assistance) to produce a score of 0 to 64.
UP to 24 months
Change From Baseline in Hammersmith Infant Neurological Examination (HINE) Section 2 (Participants aged <24 months at dosing)
大体时间:Baseline, Month 6, Month 12, Month 18, Month 24
HINE Section 2, the motor milestones portion of the HINE, includes 8 items. Total HINE score is the sum of points from each item and can range from 0 to 26. A positive change from baseline indicates a better outcome.
Baseline, Month 6, Month 12, Month 18, Month 24
Proportion of Participants Who Survival at 14 Month of Age (Participants aged <24 months at dosing).
大体时间:Up to 14 month of age
Survival is defined by the avoidance of the combined endpoint of either (a) death or (b) permanent ventilation, which is defined by tracheostomy or by the requirement of ≥ 16 hours of respiratory assistance per day (via non-invasive ventilatory support) for ≥ 14 consecutive days in the absence of an acute reversible illness, excluding perioperative ventilation.
Up to 14 month of age
Proportion of Participants Maintaining Growth Without Non-oral Nutrition at 18 Month of Age (Participants aged <24 months at dosing).
大体时间:Up to 18 month of age
The ability to maintain growth without non-oral nutrition is defined as the subject not requiring nutrition via nasogastric tube, gastric tube, enteral, parenteral, or intravenous routes, while maintaining body weight (not less than 2 standard deviations below the mean body weight for children of the same age and sex).
Up to 18 month of age
Proportion of Ventilator-independent Participants at 18 Month of Age (Participants aged <24 months at dosing).
大体时间:Up to 18 month of age
Independence from ventilator support is defined as no requirement for daily ventilator support/use in the absence of acute reversible disease, excluding perioperative ventilation.
Up to 18 month of age
Change From Baseline in Revised Upper Limb Module (RULM) Total Score (Participants aged ≥24 months and ≤60 months at dosing).
大体时间:Up to 24 months
The RULM is a specific assessment of motor performance in the upper limbs from childhood through adulthood in ambulatory and non-ambulatory individuals with SMA. The scale consists of 19 scorable items: 18 items scored on 0 (unable) to 2 (full achievement) scale, and one item that is scored from 0 (unable) to 1 (able). Total scores range from 0-37 points. Higher scores reflect higher level of motor ability.
Up to 24 months
Change From Baseline in MFM-32 Score (Participants aged ≥24 months and ≤60 months at dosing).
大体时间:Up to 24 months
The MFM-32 is a generic neuromuscular scale consisting of 32 items. Items belong to one of three different dimensions: Standing and transfers D1; Axial and proximal mobility D2; Distal motor ability D3. Each item is scored on a scale from 0 (cannot perform) to 3 (performs the task completely and normally), higher scores reflect higher level of motor ability.
Up to 24 months
Change From Baseline in Hammersmith Functional Motor Scale-Expanded (HFMSE) Score (All age groups)
大体时间:Baseline, Month 6, Month 12, Month 18, Month 24
Assess change from baseline in HFMSE score (33 items, 0-66 points).
Baseline, Month 6, Month 12, Month 18, Month 24
Proportion of Participants Who Achieve The World Health Organization (WHO) motor milestones (All age groups).
大体时间:Baseline, Month 6, Month 12, Month 18, Month 24
WHO motor milestones and performance criteria included sitting without support for at least 10 seconds, Hands-and-knees crawling at least three in a row, standing with assistance for at least 10 seconds, walking with assistance at least five steps, standing alone for at least 10 seconds, and walking alone. Assess proportion of participants achieving any new WHO motor milestone.
Baseline, Month 6, Month 12, Month 18, Month 24
Change From Baseline in CMAP (All age groups)
大体时间:Baseline, Month 6, Month 12, Month 18, Month 24
Assess motor neuron function via change from baseline in CMAP within 24 months after treatment, assessed per dose cohort independently.
Baseline, Month 6, Month 12, Month 18, Month 24

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年4月21日

初级完成 (估计的)

2028年4月23日

研究完成 (估计的)

2030年4月23日

研究注册日期

首次提交

2026年5月15日

首先提交符合 QC 标准的

2026年5月24日

首次发布 (实际的)

2026年6月1日

研究记录更新

最后更新发布 (实际的)

2026年6月1日

上次提交的符合 QC 标准的更新

2026年5月24日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅